


Dear collaborators, partners, and members of the MoLBi community,

Happy Lunar New Year and welcome to the Year of the Fire Horse. Traditionally associated with energy, courage, and forward momentum, it feels an especially fitting symbol for how we have begun 2026 at Monash Live-Biobanking. We held our first MoLBi Research Meeting of the year on 10th February. Bringing together clinicians, scientists, students, research staff, and consumer advocates, the meeting set the tone for the year ahead and reaffirmed what makes MoLBi unique: a collaborative, patient-centred initiative built on urgency, innovation, and shared purpose.



We were privileged to welcome our consumer partners Tonie, Phil and Nathan Dalton, Mark Norris, and Craig Cardinal. Their presence grounded the meeting in the lived experience of patients and families and reminded us why our work matters. Tonie and Mark spoke with honesty and clarity about what MoLBi represents for the brain cancer community as a pathway to progress, transparency, and hope for patients and carers navigating an often overwhelming diagnosis. Craig provided an update on developments within the Australian Brain Cancer Mission 2.0 and highlighted the importance of national coordination, sustained advocacy, and ensuring that patient voices continue to shape research priorities.


Justin Moore outlined a compelling vision for MoLBi in 2026 and beyond. He spoke about the urgency of delivering meaningful impact for patients with glioblastoma and other aggressive cancers and reaffirmed the three pillars guiding the program: **patient focus, clinical relevance, and technological advancement**. He emphasised the importance of accelerating translation from operating theatre to laboratory discovery and ultimately to therapeutic application. The integration of neurosurgery, oncology, molecular profiling, and preclinical modelling continues to position MoLBi as a uniquely powerful translational ecosystem capable of shortening the distance between discovery and patient benefit.



The meeting also highlighted the strong scientific momentum across the program. Tu Nguyen-Dumont shared updates from her NHMRC Ideas Grant work, illustrating how genomic discovery efforts are increasingly integrated into MoLBi workflows and helping to deepen our understanding of tumour biology. In a moment that captured the spirit of our community, Phil Dalton presented the inaugural “**Phil Chocolate Cake Award**” in recognition of major MoLBi grant achievements.

MoLBi continues to grow at an extraordinary pace. As of today, **225 participants have enrolled** in the program and **230 biospecimens** have been collected and processed. These specimens are enabling genomic, transcriptomic, and immunopeptidomic profiling while supporting the development of translational models designed to accelerate therapeutic discovery. Our Phase Zero study was recently presented at the Monash Oncology Unit feasibility meeting and received strong support. The Monash University Clinical Trial Centre has been contracted to develop two investigational drug sub-study protocols for our industry partner.

Our work gained further visibility at the Lorne Cancer Conference 2026, held from 12th-14th February, where the team presented [MoLBi: From Theatre to Therapy – Building Australia’s First Live-Biobanking Platform for Precision Immunotherapy](#), alongside [CAM-on-MoLBi: A Rapid and Scalable In Ovo Platform for Translational Cancer Modelling](#). The GBM chicken chorioallantoic membrane model attracted significant interest as a rapid and scalable system for testing therapeutic strategies.



MoLBi was featured in **2 grant submissions to the MRFF Australian Brain Cancer Mission 2025**, reflecting increasing national recognition of the platform’s importance in accelerating discovery and enabling clinical translation. We are delighted to announce that Monash Oncology Research Initiative (MORI) Fellowship funding will continue to support the program for another year, ensuring continuity and momentum.

As we move into 2026, we remain focused on strengthening the bridge between surgery and science, discovery and treatment, and research and lived experience. The continued expansion of live tumour collection, integration of advanced molecular profiling, development of translational models, and embedding of consumer partnership will be central to our efforts to accelerate precision immunotherapy and early phase clinical translation.

Our next MoLBi Research Meeting will be held on **Tuesday 10th March 2026 at 4:00 pm**. All members, students, and collaborators are warmly encouraged to attend.

Thank you to everyone, including clinicians, researchers, consumers, donors, and partners, whose dedication continues to drive MoLBi forward.

With best wishes,



Dr Gwo Yaw Ho
Founder and Chair, Monash Live-Biobanking



Professor Justin Moore
Director of Neurosurgery, Monash Health